Zobrazeno 1 - 10
of 1 646
pro vyhledávání: '"Albumin binding"'
Autor:
Fatemeh Shafiee, Ali Yazdani
Publikováno v:
Research in Pharmaceutical Sciences, Vol 19, Iss 3, Pp 356-365 (2024)
Background and purpose: Anakinra must be injected daily due to its short half-life and this leads to lower patient compliance. Therefore, the aim of this study was to produce an interleukin-1 receptor antagonist (IL-1Ra) with albumin binding domain (
Externí odkaz:
https://doaj.org/article/f78eba8011f5450bb6e5f5477d9b79ad
Autor:
Soumen Saha, Samagya Banskota, Parisa Yousefpour, Jeffrey L. Schaal, Nikita Zakharov, Jianqiao Liu, Michael Dzuricky, Ziwei He, Stefan Roberts, Xinghai Li, Ashutosh Chilkoti
Publikováno v:
Small Science, Vol 4, Iss 11, Pp n/a-n/a (2024)
Nab‐paclitaxel (Abraxane), an albumin‐bound solvent‐free paclitaxel (PTX) formulation that takes advantage of the endogenous albumin transport pathway, is the current gold standard for treatment of solid tumors with PTX. However, nab‐paclitax
Externí odkaz:
https://doaj.org/article/f24ec2aa4c224b659763f6bcc87b8c31
Autor:
Hiroo Imai, Yasuhiro Sakamoto, Shin Takahashi, Hiroyuki Shibata, Atsushi Sato, Kazunori Otsuka, Kenji Amagai, Masanobu Takahashi, Takuhiro Yamaguchi, Chikashi Ishioka
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-8 (2024)
Abstract Background Advanced pancreatic cancer is one of the leading causes of cancer-related deaths. For patients with advanced pancreatic cancer, gemcitabine and nanoparticle albumin-binding paclitaxel (nabPTX) combination (GEM/nabPTX) therapy is o
Externí odkaz:
https://doaj.org/article/5310443217344e7f9c587dac657eb026
Publikováno v:
MedComm, Vol 5, Iss 5, Pp n/a-n/a (2024)
Abstract Single‐domain antibody–drug conjugates (sdADCs) have been proven to have deeper solid tumor penetration and intratumor accumulation capabilities due to their smaller size compared with traditional IgG format ADCs. However, one of the key
Externí odkaz:
https://doaj.org/article/a82ab916581c41bf94b1b718a6ead906
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Cancer is a leading cause of death worldwide. Several targeted anticancer drugs entered clinical practice and improved survival of cancer patients with selected tumor types, but therapy resistance and metastatic disease remains a challenge. A major c
Externí odkaz:
https://doaj.org/article/a40c267efb8c445dae45a258548ed0a3
Publikováno v:
Future Journal of Pharmaceutical Sciences, Vol 9, Iss 1, Pp 1-11 (2023)
Abstract Background Multidrug regimens can increase the risk of drug–drug interactions at the level of albumin binding especially for drugs with narrow therapeutic windows such as carbamazepine (CBZ). This risk is particularly heightened for CBZ wh
Externí odkaz:
https://doaj.org/article/4e2960f49cd940d983219f3f3c49c592
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Richard T. Kenney, John K. Cini, Susan Dexter, Manuel DaFonseca, Justus Bingham, Isabelle Kuan, Sant P. Chawla, Thomas M. Polasek, Jason Lickliter, Philip J. Ryan
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundThe benefits of recombinant interleukin-12 (rIL-12) as a multifunctional cytokine and potential immunotherapy for cancer have been sought for decades based on its efficacy in multiple mouse models. Unexpected toxicity in the first phase 2 s
Externí odkaz:
https://doaj.org/article/9baead1eb8e549ccaed6f20a613f9c70
Publikováno v:
Heliyon, Vol 10, Iss 2, Pp e24340- (2024)
In recent years, glucagon-like peptide-1 (GLP-1) has demonstrated considerable potential in the treatment of type 2 diabetes (T2D) and obesity. However, the half-life of naturally occurring GLP-1 is quite short in vivo. Two common strategies employed
Externí odkaz:
https://doaj.org/article/69f42efadd3e4c639fab3490d3362114
Autor:
John K. Cini, Susan Dexter, Darrel J. Rezac, Stephen J. McAndrew, Gael Hedou, Rich Brody, Rukiye-Nazan Eraslan, Richard T. Kenney, Pankaj Mohan
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
BackgroundThe potential synergy between interleukin-12 (IL-12) and IL-15 holds promise for more effective solid tumor immunotherapy. Nevertheless, previous clinical trials involving therapeutic cytokines have encountered obstacles such as short pharm
Externí odkaz:
https://doaj.org/article/ec5b713791af4cd19df56d27a6cab5cc